OIPE JC#03 APR 06 2004 PATENT & TRADEMARK OFFICE

Express Mail Label No.: EV399525755US
Date of Deposit: April 6, 2004

OIPE IAP2 JAN 11 2006 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) in this box [+]

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/665,079
	Filing Date	09/16/03
	First Named Inventor	Bacopoulos
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	24852-501 CIP5

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1*	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
	B2*	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
	B3*	WO	00/71703	Methylgene, Inc.	November 30, 2000	X	
	B4*	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X	
	B5*	WO	01/38322	Methylgene, Inc.	May 31, 2001	X	
	B6*	WO	01/70675	Methylgene, Inc.	September 27, 2001	X	
	B7*	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X	
	B8*	WO	02/30879	Prolifix Limited	April 18, 2002	X	
	B9*	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Andrews et al. (2000). *Intl. J. Parasitol.* 30: 761-768.
	C2*	Archer et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract 4611.
	C4*	Butler et al. (2000). *Cancer Res.* 60: 5165-5170.
	C5*	Butler et al. (2001). *Clincal Cancer Res.* 7: 962-970.
	C6*	Butler et al. (2002). *Proc. Natl. Acad. Sci. USA* 99: 11700-11705.
	C7*	Coffey et al. (2000). *Medical and Pediatric Oncology* 35: 577-581.

I Did not receive

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8*	Coffey et al. (2001). *Cancer Res.* 61: 3591-3594.
	C9*	Cohen et al. (1999). *Anticancer Res.* 19: 4999-5006.
	C10*	Cohen et al. (2002). *Anticancer Res.* 22: 1497-1504.
	C11*	Curtin (2002). *Exp. Opin. Ther. Patents* 12: 1375-1384.
	C12*	Dressel (2000). *Anticancer Res.* 20: 1017-1022.
	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology Abstract No. **4602**.
	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract No. **3195**.
	C15*	Finnin et al. (1999). *Nature* 401: 188-193.
	C16*	Furamai et al. (2001). *Proc. Natl. Sci. USA* 98: 87-92.
	C17*	Grunstein (1997). *Nature* 389: 349-352.
	C18*	He et al. (2001). *J. Clin. Investigation* 108: 1321-1330.
	C19*	Hockly et al. (2003). *Proc. Natl. Acad. Sci. USA* 100: 2041-2046.
	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." *American Society of Clinical Oncology*, Abstract No. **344**.
	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." *American Society of Clinical Oncology*, 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. **1831**.
	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." *European J. Cancer* 38(Suppl. 7): 88, Abstract No. **286**.
	C23*	Kim et al. (1999). *Oncogene* 18: 2461-2470.
	C24*	Kohge et al. (1998). *Biochem. Pharmacol.* 56: 1359-1364.
	C25*	Komatsu et al. (2001). *Cancer Res.* 61: 4459-4466.
	C26*	Kouraklis and Theocharis (2002). *Curr. Med. Chem.Anti-Cancer Agents* 2: 477-484.
	C27*	Lee et al. (2001). *Cancer Res.* 61: 931-934.
	C28*	Lin et al. (1998). *Nature* 391: 811-814.
	C29*	Mai et al. (2001). *OPPI Briefs* 33: 391-394
	C30*	Marks et al. (2000). *J. of the Natl. Cancer Institute* 92: 1210-1215.
	C31*	Marks et al. (2001). *Clinical Cancer Res.* 7: 759-760.
	C32*	Marks et al. (2001). *Curr. Opin. In Oncology* 13: 477-483.
	C33*	Marks et al. (2001). *Nature Reviews* 1: 194-202.
	C34*	Miller et al. (2003). *J Med Chem.* 46: 5097-5116.
	C35*	Munster et al. (2001). *Cancer Res.* 61: 8492-8497.
	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." *American Society of Clinical Oncology*, December 6-10, 2002, Abstract No. **4742**.
	C37*	Qui et al. (2000). *Mol. Biol. Cell* 11: 2069-2083.
	C38*	Richon et al. (1996). *Proc. Natl. Acad. Sci. USA* 93: 5705-5708.
	C39*	Richon et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 3003-3007.
	C40*	Richon et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 10014-10019.
	C41*	Richon and O'Brien (2002). *Clinical Cancer Res.* 8: 662-664.
	C42*	Saito et al. (1999). *Proc. Natl. Acad. Sci. USA* 96: 4592-4597.
	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

, Did not receive

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Radiation in Human Prostate Tumor Spheroids." *American Society of Clinical Oncology*, Abstract No. 105.
	C44*	Stowell et al. (1995). *J. Med. Chem.* 38: 1411-1413.
	C45*	Su et al. (2000). *Cancer Res.* 60: 3137-3142.
	C46*	Suzuki et al. (1999). *J. Med. Chem.* 42: 3001-3003.
	C47*	Van Lint et al. (1996). *Gene Expression* 5: 245-253.
	C48*	Vrana et al. (1999). *Oncogene* 18: 7016-7025.
	C49*	Webb et al. (1999). *J. Biol. Chem.* 274: 14280-14287.
	C50*	Yoshida et al. (1990). *J. Biol. Chem.* 265: 17174-17179.
	C51*	Yoshida et al. (1995). *BioEssays* 17: 423-430.
	C52*	Zhou et al. (1999). *Gene* 233: 13-19.
	C53*	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 1056-1061.
	C54*	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 14329-14333.
	C55*	Zhou et al. (2001). *Proc. Natl. Acad. Sci. USA* 98: 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. **10/379,149**, filed **March 4, 2003**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Did not receive

Express Mail Label No.: EV334317572US
Date of Deposit: February 26, 2004

OIPE JC71 FEB 26 2004 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) in this box [+]

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/379,149
Filing Date	March 4, 2003
First Named Inventor	Victoria M. Richon and Judy H. Chiao
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	24852-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No
	B1	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
	B2	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
	B3	WO	00/71703	Methylgene, Inc.	November 30, 2000	X	
	B4	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X	
	B5	WO	01/38322	Methylgene, Inc.	May 31, 2001	X	
	B6	WO	01/70675	Methylgene, Inc.	September 27, 2001	X	
	B7	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X	
	B8	WO	02/30879	Prolifix Limited	April 18, 2002	X	
	B9	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Andrews et al. (2000). *Intl. J. Parasitol.* 30: 761-768.
	C2	Archer et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 6791-6796.
	C3	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract **4611**.
	C4	Butler et al. (2000). *Cancer Res.* 60: 5165-5170.
	C5	Butler et al. (2001). *Clincal Cancer Res.* 7: 962-970.
	C6	Butler et al. (2002). *Proc. Natl. Acad. Sci. USA* 99: 11700-11705.
	C7	Coffey et al. (2000). *Medical and Pediatric Oncology* 35: 577-581.

OIPE JC71
FEB 26 2004
PATENT & TRADEMARK OFFICE

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8	Coffey et al. (2001). *Cancer Res.* 61: 3591-3594.
	C9	Cohen et al. (1999). *Anticancer Res.* 19: 4999-5006.
	C10	Cohen et al. (2002). *Anticancer Res.* 22: 1497-1504.
	C11	Curtin (2002). *Exp. Opin. Ther. Patents* 12: 1375-1384.
	C12	Dressel (2000). *Anticancer Res.* 20: 1017-1022.
	C13	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology Abstract No. **4602**.
	C14	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract No. **3195**.
	C15	Finnin et al. (1999). *Nature* 401: 188-193.
	C16	Furamai et al. (2001). *Proc. Natl. Sci. USA* 98: 87-92.
	C17	Grunstein (1997). *Nature* 389: 349-352.
	C18	He et al. (2001). *J. Clin. Investigation* 108: 1321-1330.
	C19	Hockly et al. (2003). *Proc. Natl. Acad. Sci. USA* 100: 2041-2046.
	C20	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." *American Society of Clinical Oncology*, Abstract No. **344**.
	C21	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." *American Society of Clinical Oncology*, 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. **1831**.
	C22	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." *European J. Cancer* 38(Suppl. 7): 88, Abstract No. **286**.
	C23	Kim et al. (1999). *Oncogene* 18: 2461-2470.
	C24	Kohge et al. (1998). *Biochem. Pharmacol.* 56: 1359-1364.
	C25	Komatsu et al. (2001). *Cancer Res.* 61: 4459-4466.
	C26	Kouraklis and Theocharis (2002). *Curr. Med. Chem.-Anti-Cancer Agents* 2: 477-484.
	C27	Lee et al. (2001). *Cancer Res.* 61: 931-934.
	C28	Lin et al. (1998). *Nature* 391: 811-814.
	C29	Mai et al. (2001). *OPPI Briefs* 33: 391-394
	C30	Marks et al. (2000). *J. of the Natl. Cancer Institute* 92: 1210-1215.
	C31	Marks et al. (2001). *Clinical Cancer Res.* 7: 759-760.
	C32	Marks et al. (2001). *Curr. Opin. In Oncology* 13: 477-483.
	C33	Marks et al. (2001). *Nature Reviews* 1: 194-202.
	C34	Miller et al. (2003). *J Med Chem.* 46: 5097-5116.
	C35	Munster et al. (2001). *Cancer Res.* 61: 8492-8497.
	C36	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." *American Society of Clinical Oncology*, December 6-10, 2002, Abstract No. **4742**.
	C37	Qui et al. (2000). *Mol. Biol. Cell* 11: 2069-2083.
	C38	Richon et al. (1996). *Proc. Natl. Acad. Sci. USA* 93: 5705-5708.
	C39	Richon et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 3003-3007.
	C40	Richon et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 10014-10019.
	C41	Richon and O'Brien (2002). *Clinical Cancer Res.* 8: 662-664.
	C42	Saito et al. (1999). *Proc. Natl. Acad. Sci. USA* 96: 4592-4597.
	C43	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

OIPE JC71
FEB 26 2004
PATENT & TRADEMARK

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Radiation in Human Prostate Tumor Spheroids." *American Society of Clinical Oncology*, Abstract No. 105.
	C44	Stowell et al. (1995). *J. Med. Chem.* 38: 1411-1413.
	C45	Su et al. (2000). *Cancer Res.* 60: 3137-3142.
	C46	Suzuki et al. (1999). *J. Med. Chem.* 42: 3001-3003.
	C47	Van Lint et al. (1996). *Gene Expression* 5: 245-253.
	C48	Vrana et al. (1999). *Oncogene* 18: 7016-7025.
	C49	Webb et al. (1999). *J. Biol. Chem.* 274: 14280-14287.
	C50	Yoshida et al. (1990). *J. Biol. Chem.* 265: 17174-17179.
	C51	Yoshida et al. (1995). *BioEssays* 17: 423-430.
	C52	Zhou et al. (1999). *Gene* 233: 13-19.
	C53	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 1056-1061.
	C54	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 14329-14333.
	C55	Zhou et al. (2001). *Proc. Natl. Acad. Sci. USA* 98: 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____ , filed _____ , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.